Document is current
Any future updates will be listed below
-
Authors
Chauveau, Léa
Gonneaud, Julie
Poisnel, Géraldine
Landeau, Brigitte
Garnier-Crussard, Antoine
Pitel, Anne-Lise
Roquet, Daniel
Touron, Edelweiss
Haudry, Sacha
Mezenge, Florence
Chocat, Anne
Vivien, Denis
de La Sayette, Vincent
Chételat, Gaël
de Flores, Robin
,
-
Funding
Funding for this research was provided by:
Fondation Recherche Alzheimer
Fondation Alzheimer
Fondation de France
European Union’s Horizon 2020 research and innovation program (Grant 667696)
Région Normandie (Label d’Excellence)
Fondation d’Entreprise MMA des Entrepreneurs du Futur
- License Information
-
More Information
Article History
Received: 13 March 2025
Accepted: 2 July 2025
First Online: 15 July 2025
Declarations
:
: All participants provided written informed consent prior to participation. The Age-Well trial was approved by the Nord Ouest III ethics committee (Caen, France) and sponsored by the Institut National de la Santé et de la Recherche Médicale (Clinicaltrials.gov Identifier: NCT02977819; trial registration number: EudraCT: 2016–002441-36; IDRCB: 2016-A01767-44; registration date: 2016–11–25).
: The authors declare no competing interests.
